Oncopeptides - Hoffnung bringen durch Wissenschaft

Bring hope through science

Oncopeptides is a global biotech company, founded in Sweden, focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and is committed to bringing innovation to patients with an unmet need and improving patient lives.

Jakob Lindberg, CEO

CEO Jakob Lindberg

Science is leading the way

"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"

Jakob Lindberg, CEO

Multiple myeloma

Multiple myeloma is a cancer of the bone marrow that results in production of abnormal blood plasma cells. The disease is linked to substantial morbidity and mortality, and there is currently no cure. Patients being treated for multiple myeloma will experience symptom free periods, but they will relapse as the disease develops resistance to the treatment.

Multiple myeloma is a plasma cell neoplasmMultiple myeloma in numbers

Classic CRAB symptoms

Disease course

Relapsed and Refractory Multiple Myeloma

Extramedullary disease

Extramedullary disease 2

The incurable nature of multiple myeloma



To the ESMO Paris event